Juno Pharmaceuticals Gains Momentum with Acquisition of Omega Laboratories, Strengthening Canada’s Pharmaceutical Sector

Today, Juno Pharmaceuticals Canada (“Juno”) has taken a major step forward in the commercialization of specialty pharmaceuticals, with the acquisition of Omega Laboratories (“Omega”) – one of Canada’s largest domestic specialty injectable pharmaceutical manufacturers. This strategic move has created a powerhouse in the Canadian specialty generics injectable space, solidifying Juno’s position as a leader in the industry.

Juno is proud to announce the acquisition of an important pharmaceutical asset that will strengthen our ability to supply critically needed medications to healthcare systems everywhere. As a Canadian-owned and operated company, we are committed to providing high-quality Canadian-made pharmaceuticals to domestic and international markets. This acquisition is an important step towards our goal of delivering reliable, safe drugs to those who need them.

Juno and Omega have joined forces to revolutionize healthcare, bringing over 100 new products to the Canadian market in the next four years. From pain management and oral solutions to allergy vaccines, diabetes and weight-loss, Juno and Omega are on a mission to provide medical practitioners and patients with the essential pharmaceutical products they need.

Plus, Juno is also developing unique offerings in the dental, cosmetic, and animal health sectors. With Juno’s robust commercial network and product development pipeline, and Omega’s Health Canada and U.S. FDA approved injectable manufacturing facility, these two companies are paving the way to a healthier future.

At a time when Canada’s healthcare system is vulnerable to the global market and facing drug shortages, Juno is stepping in to provide much-needed relief. The new partnership between Juno and a Canadian manufacturing facility will bolster domestic manufacturing capabilities, aiding in bringing stability to the healthcare system and providing immediate relief for many of the drug shortages presently facing patients. By doing so, Juno will help to prevent further drug shortages and ensure access to essential pharmaceuticals.

By joining forces, Omega’s manufacturing know-how and Juno’s commercial power are driving a powerful combination within Canada’s pharmaceutical industry. We are dedicated to providing Canadians with top-notch medications and to investing in our domestic production, safeguarding and creating jobs, while helping to increase our self-sufficiency in the domestic pharmaceutical market. Our ambitions are even greater as we look to extend our reach beyond Canada’s borders.

Juno is revolutionizing the Canadian specialty pharmaceutical market with a flurry of innovative new products, making it the fastest-growing domestic business in the industry!

Juno, a leading payments company, recently acquired Payment Rails, a cross-border payment platform. To assist with the acquisition, Juno was supported by the expertise of Burton Securities Inc. as financial advisor, and legal counsel from Aird & Berlis LLP. With the successful completion of the acquisition, Juno is now well-positioned to expand its presence in the payments industry.

About Juno Pharmaceuticals Canada

Juno Pharmaceuticals Canada is a frontrunner in the development and delivery of high-quality, cost-effective, complex, and high value generics, branded, and biosimilar medication. Boasting operations in both Toronto and Montreal, Juno ranks among the most extensive generic injectable providers in Canada with an expansive distribution network across 22 international locations.

As part of the global Juno Pharmaceuticals group, Juno’s multinational operations span four continents and consist of more than 14 specialized pharmaceutical and medical device businesses in Canada, the United Kingdom, the European Union, Australia, and South Africa.

Leave a Comment